Maynard Um
-
-
-
-
-
-
-
Immunovant reports mixed trial results for IMVT-1402 in rheumatoid arthritis
-
-
-
-
-
-
-
Immunovant, Inc. (IMVT) Tops Q3 EPS by 11c
-
-
-
-
-
-
-
Truist Securities Starts Immunovant (IMVT) at Hold
-
-
-
-
-
-
-
Goldman Sachs Resumes Immunovant (IMVT) at Neutral
-
-
-
-
-
-
-
Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies
-
-
-
-
-
-
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)
-
433,570 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

